Common Contracts
8 similar Securities Purchase Agreement contracts by Biotime Inc, OncoCyte Corp, NLS Pharmaceutics Ltd., others
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 8th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 6, 2022, by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers” or “BVF”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 12th, 2020 • SANUWAVE Health, Inc. • Surgical & medical instruments & apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 6, 2020, between SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and HealthTronics, Inc. (the “Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 13th, 2017 • Soleno Therapeutics Inc • Electromedical & electrotherapeutic apparatus • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of December 11, 2017, between Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2016, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2016 • OncoCyte Corp • In vitro & in vivo diagnostic substances • California
This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2016, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2016 • OncoCyte Corp • In vitro & in vivo diagnostic substances • California
This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2016, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2016, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 2nd, 2013 • Parkervision Inc • Radio & tv broadcasting & communications equipment • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2013, between Parkervision, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
